Boston Scientific Corporation(BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Latest News & Analysis
Boston Scientific (BSX) Q2 2025 Analysis: Cardiovascular Innovation Drives Strong Growth
Boston Scientific's Q2 2025 results reveal robust revenue growth driven by cardiovascular segment innovation and strategic acquisitions, highlighting strong fundamentals.
Boston Scientific (BSX) Q2 2025 Earnings Analysis: FARAPULSE & WATCHMAN Drive Growth Surge
Boston Scientific's Q2 2025 earnings beat estimates, led by FARAPULSE and WATCHMAN growth, with raised guidance reflecting strong Cardiovascular segment momentum.
Boston Scientific (BSX) Q2 2025 Analysis: PFA System Growth and Market Leadership
Boston Scientific's FARAPULSE™ PFA system drives strong Q2 2025 growth amid competitive electrophysiology market, backed by robust financials and strategic innovation.
Boston Scientific Corporation PFA Strategy Drives Electrophysiology Leadership and Robust Financial Growth
Boston Scientific's Farapulse PFA technology and FDA approvals fuel market leadership in electrophysiology, driving strong revenue growth and strategic expansion.
Boston Scientific (BSX) FDA Approval of FARAPULSE PFA and Strategic Market Growth Analysis
Boston Scientific's FARAPULSE PFA system gains FDA approval, driving innovation and growth in cardiac ablation. Financials and market positioning analyzed.
Boston Scientific Corporation BSX FARAPULSE FDA Approval Drives Market Growth and Investor Confidence
Boston Scientific's FARAPULSE FDA approval for persistent AFib expands market share potential, boosts MedSurg growth, and sets stage for strong Q2 2025 earnings.
Boston Scientific Corporation (BSX) Deep Dive: PFA & WATCHMAN Drive 2025 Growth
Explore Boston Scientific's 2025 growth fueled by PFA Farapulse sales, WATCHMAN device expansion, and strategic acquisitions shaping its cardiology leadership.
Boston Scientific Corporation (BSX) Growth Catalysts and Financial Performance Analysis
Explore Boston Scientific's latest growth drivers, including PFA and WATCHMAN innovations, strategic acquisitions, and detailed financial insights shaping BSX's market position.
Boston Scientific (BSX) Growth: PFA, Neuromodulation, & M&A Catalysts
Boston Scientific (BSX) showcases robust Q1 2025 performance, driven by PFA innovation, neuromodulation advancements, and strategic acquisitions.
Boston Scientific (BSX) Q1 2025: Strategic Growth & Financial Strength
Boston Scientific's Q1 2025 saw a 1.2% stock rise, driven by strong revenue growth, strategic acquisitions, and robust medical device demand.
Boston Scientific (BSX) Q1 2025: Strong Growth & Strategic Focus
Boston Scientific's Q1 2025 net sales surged +20.9% to $4.663 billion, driven by strong cardiovascular segment growth and key product innovations like FARAPULSE.
Boston Scientific's Growth Trajectory: Navigating M&A, Innovation, and Regulatory Headwinds
Analysis of Boston Scientific's strong financial growth, strategic acquisitions, key clinical trial successes, and challenges in the evolving regulatory landscape.
Boston Scientific (BSX) Navigates Strategic Pivot After Heart Device Discontinuation
Boston Scientific recently discontinued its Acurate neo2 heart device program, citing regulatory hurdles and trial results. This analysis explores the financial and strategic implications.
Boston Scientific (BSX) Q1 2025 Earnings Preview: Key Metrics, Valuation, and Strategic Moves
Ahead of Q1 2025 earnings, Boston Scientific (BSX) faces scrutiny on valuation amidst strong growth expectations and strategic moves like the SONIVIE acquisition.
Boston Scientific (BSX): Q1 2025 Earnings, Growth Strategy
Analysis of Boston Scientific's (BSX) Q1 2025 earnings expectations, growth strategy, and competitive landscape amid global economic uncertainties.
Boston Scientific (BSX): Growth, Innovation, and Market Challenges
Analysis of Boston Scientific (BSX): global expansion, WATCHMAN FLX performance, AI integration, and financial health amid market challenges.
Boston Scientific: AI, Acquisitions, and Growth Analysis
Boston Scientific strategically leverages AI and acquisitions to drive growth. WATCHMAN device and SoniVie acquisition are key catalysts.
Boston Scientific (BSX) Analysis: Acquisition, Innovation, and Market Strategy
Boston Scientific (BSX) navigates growth through strategic acquisitions, WATCHMAN device strength, and financial management amidst macroeconomic challenges and competitive pressures.
Boston Scientific (BSX): Acquisition, Innovation, and Growth Strategy
Boston Scientific (BSX) is strategically growing through acquisitions and innovation. The SoniVie acquisition enhances their renal denervation therapy offerings.
Boston Scientific Update: Acquisition & Financial Strategy
Intraday BSX update highlights strategic acquisitions, senior notes issuance, and robust financial performance from verified data.
Boston Scientific (BSX): Growth, Innovation, and Market Outlook in 2025
Boston Scientific navigates 2025 with strategic EMEA expansion, senior notes offering, and a focus on innovation. Key insights for investors and stakeholders.
Boston Scientific: Growth, Innovation, and EMEA Expansion in 2025
Boston Scientific navigates 2025 with strong growth, EMEA expansion, and strategic financial moves. Key products like Farapulse drive innovation amidst competition.
Boston Scientific: Growth, Innovation, and Market Expansion in 2025
Boston Scientific is poised for growth in 2025, driven by strong revenue projections and strategic global expansion. However, debt management and competition pose challenges.
Boston Scientific: Navigating Growth in the Medical Device Market 2025
In-depth analysis of BSX’s growth strategy, innovation, and EMEA expansion driving sustainable performance in 2025.
Boston Scientific Corporation: Industry Impact and Market Trends Analysis
Boston Scientific (BSX) navigates strong growth prospects amid competitive pressures and EMEA expansion, according to Monexa AI data.
Boston Scientific: Growth Fueled by Innovation and Strategic EMEA Expansion
Explore Boston Scientific's (BSX) growth strategy focusing on EMEA expansion, innovative Farapulse technology, acquisitions, and a competitive market outlook.